Ondine to present poster at IP2023, Liverpool

Ondine Biomedical Inc.

10 October 2023

 

10 October 2023

ONDINE BIOMEDICAL INC. 

("Ondine Biomedical", "Ondine" or the "Company") 

Ondine to present poster at IP2023 meeting, Liverpool

Ondine Biomedical will be presenting new research at the Infection Prevention Society 2023 Conference in Liverpool, UK

Canadian life sciences company Ondine Biomedical Inc. (LON: OBI) will present results from a new in vitro study at the IP2023 Annual Conference taking place in Liverpool from 17-19 October 2023. The study evaluated the efficacy of antimicrobial photodynamic therapy (aPDT, also known as photodisinfection) against multidrug-resistant (MDR) and extensively drug-resistant (XDR) bacteria. IP2023 is organized by the Infection Prevention Society and is the largest annual infection prevention conference in the UK and Ireland.

Antimicrobial resistance (AMR) remains a major public health concern, causing 33,000 deaths in Europe annually.[1] There are widespread multidrug-resistant (MDR) and extensively drug-resistant (XDR) infections in Europe, mainly caused by Gram-negative bacteria including Enterobacteriaceae and P. aeruginosa AMR bacteria[2]^,[3] and Gram-positive bacteria such as Staphylococcus spp.[4]

Photodisinfection uses a photosensitizer and a specific wavelength of light to trigger photochemical reactions that produce reactive oxygen species. These reactive oxygen species are lethal to a broad spectrum of microbes, including bacteria, fungi, and viruses. Importantly, photodisinfection does not induce antimicrobial resistance formation.

Photodisinfection is an easy-to-use alternative to topical antibiotics and antifungals because it is highly effective against all types of disease-causing pathogens, including MDR and XDR strains.

The poster presentation, "Antimicrobial Photodynamic Therapy Against Extensively Drug-Resistant (XDR) Gram Negative Isolates With Novel Antibiotic Resistance Factors", will be presented at IP2023 between 1:10pm and 2:40pm (BST) on 18 October 2023. A further announcement providing more details of the research will be released by the Company concurrent with the start of the presentation.

Ondine Biomedical Inc.
Carolyn Cross, CEO	+001 [phone]
Singer Capital Markets (Nominated Adviser and Joint Broker)
Aubrey Powell, Asha Chotai, Sam Butcher	[phone]
RBC Capital Markets (Joint Broker)
Rupert Walford, Kathryn Deegan	[phone]
Vane Percy & Roberts (Media Contact)
Simon Vane Percy, Amanda Bernard	[phone]

About Ondine Biomedical Inc.

Ondine Biomedical Inc. is a Canadian headquartered company innovating in the field of photodisinfection therapies. Ondine has a pipeline of investigational products, based on its proprietary photodisinfection platform, in various stages of development. Products beyond nasal photodisinfection include therapies for a variety of medical indications such as chronic sinusitis, ventilator-associated pneumonia, burns, and other indications.  

---

[1] WHO Regional Office for Europe/European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe 2022 - 2020 data. Copenhagen: WHO Regional Office for Europe; 2022.

[2] Cassini A, Högberg LD, Plachouras D, et al. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis. Lancet Infect Dis. 2019;19(1):56-66. doi:10.1016/S1473-3099(18)30605-4

[3] Karakonstantis S, Kritsotakis EI, Gikas A. Pandrug-resistant Gram-negative bacteria: a systematic review of current epidemiology, prognosis and treatment options. J Antimicrob Chemother. 2020;75(2):271-282. doi:10.1093/jac/dkz401

[4]UK Health Security Agency. MRSA, MSSA, Gram-negative bacteraemia and CDI: 30-day all-cause fatality, London: UK Health Security Agency, March 2023.

 

END